Exane Derivatives Blueprint Medicines Corp Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Exane Derivatives holds 8 shares of BPMC stock, worth $1,035. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8
Previous 567
98.59%
Holding current value
$1,035
Previous $36,000
100.0%
% of portfolio
0.0%
Previous 0.01%
Shares
9 transactions
Others Institutions Holding BPMC
# of Institutions
383Shares Held
67.7MCall Options Held
1.54MPut Options Held
1.07M-
Black Rock Inc. New York, NY6.65MShares$861 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.64MShares$860 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.42MShares$701 Million0.06% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.85MShares$498 Million5.51% of portfolio
-
Wellington Management Group LLP Boston, MA3.07MShares$398 Million0.05% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $7.73B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...